My Passport
News and Commentary education Live Coronavirus Dashboard
S&P 500 ETF
0.00%
NASDAQ ETF
0.00%
Dow Jones ETF
0.00%


Gap's Growth Drivers: Market Share Gains, Bra...
S&P 500 Faces Volatile 2025 As 'Inflation Boo...
DOJ Targets Google Chrome, Poll Shows 64% Opp...
Nike's Worst May Nearly Be Over: Analyst Sees...
European Commission Downgrades EU GDP Growth...
Pfizer Stock Drops 10% In November On News Of...
Best Buy's Growth Hinges On Computing And Ser...
3 ETFs With PLTR Exposure To Consider As Nasd...
The Rise of the Solo General Partner Investor

While modern day venture capital originated in the 1940s, the very first iteration of venture capital (VC) investments--where a general partner (GP) investments capital on behalf of a limited partner (LP)--dates all the way back to the early 1600s with the founding of East India...

  • How are Higher Rates Impacting the Housi...
  • Quantitative Tightening: How the Fed Co...
  • Should Investors Worry About Inflation?
  • How Semiconductors are Made and Why its...
  • What Are NFTs?
    • Inflation: What is it and How to Protect From...
    Short Squeezes Could Lead to Market Dislocati...
    How Google and Facebook Antitrust Lawsuits Co...
    Vaccine News Triggers Growth to Value Rotatio...
    Energy
    Materials
    Industrial
    Finance
    Consumer D...
    Consumer S...
    Informatio...
    Telecommun...
    Health Car...
    Utilities
    Oil
    Gold
    ETFs IPOs Ratings
     
    S&P 500 ETF
    0.00%
    NASDAQ ETF
    0.00%
    Dow Jones ETF
    0.00%
    Search
    News and Commentary
    Education
    Market
    ETFs
    IPOs
    Ratings
    Newsfeed
    My passport
    Login
    Sign up

    NOVARTIS AG ADR-EACH REPR 1 CHF0.5(REGD) (NYSE: NVS)

    Overview
    current price
    $104.28
    $104.28
    change
    0.43 | 0.41%
    0.43 | 0.41%
    Yesterday's Close
    103.85
    open
    104.44
    volume
    1.34 M
    30d. avg volume.
    1.20 M
    1 day
    104.18 - 105.19
    52 weeks
    92.35 - 120.92
    p/e
    25.25
    beta
    0.5760
    market cap
    228.37 B
    dividend yield
    0.00%
    Industry
    -
    NVS by TradingView
    News and Commentary
    US HHS Reveal Cost Savings For 54 Prescription Drugs Including Novartis' Cancer Drug, Ozempic Could... Monday, the U.S. Department of Health and Human Services (HHS) announced that Medicare enrollees will benefit from reduced prices on 54 drugs through Medicare Part B, effective f...
    Novartis' Q2 Earnings: Revenue And EPS Beat, Raises 2024 Profit Forecast On Strong Demand For Key Dr... Swiss pharma giant Novartis AG (
    Market Update: S&P 500, Nasdaq Retreat, Dow Climbs 200 Points on Stock Rotation The S&P 500 Index and Nasdaq Composite slipped lower on Wednesday as investors rotated out of semiconductor names and into more rate sensitive names. This, in turn, lead the Dow...
    After UnitedHealth Cyberattack, Drug Distributor Cencora Notifies Americans' Health Information Stol... U.S. drug wholesaler Cencora Inc (
    Google DeepMind Develops Latest AI Model To Aid Scientists In Fighting Disease Researchers at Alphabet Inc's (
    Market Update: Dow Climbs 260 Points on Strong Second-Quarter Earnings Stocks climbed higher on Tuesday as the second-quarter earnings season delighted investors, helping to build on gains from the prior session. The Dow Jones Industrial Average ros...
    Amazon, Alphabet, Meta, Intel Q3 Earnings This Week: Will Mega-Caps Shatter Forecasts And Revive Mar... After the first week of earnings, analysts have tempered their expectations for profit growth, anticipating a continuation of the profit-declining trend.
    Drugmakers Agree To Participate For Medicare Drug Price Negotiation With Biden Administration All ten manufacturers of the first drugs selected for Medicare price negotiations will be participating, the White House said, even though many of them are suing the administrati...
    Novartis Sandoz Prepares For Public Debut With Strong Sales Record And Plans for New Biologic Drugs Novartis AG (NVS 
    From Years to Months: How AI is Shaping the Landscape of Clinical Trials Pharmaceutical companies are harnessing artificial intelligence (AI) to speed up the traditionally arduous process of clinical trials, potentially saving both time and significan...
    StockTwits
    StockTwits
    Most Shared
    SolarEdge Q3 Results Miss Expectations; Analysts Warn Of Cash Flow Challenges And Need For Cost Cuts
    US Economy Grows Less Than Expected In Q3, Yet Private Employment Soars By 233,000 In October
    Netflix Crash Hits Jake Paul-Mike Tyson Fight: Can Streaming Platform Handle Christmas Day NFL Action?
    Most Popular
    Meta, Amazon, Microsoft Partner On Defense AI Initiative
    Palantir Overtakes Lockheed Martin In Market Cap, How Does The 'Messi Of AI' Stack Up Against The Traditional Defense Player
    Ford CEO Jim Farley Says He Tries To Drive All Vehicles From Competition After Expressing Adoration For Xiaomi SU7: 'Try Me,' Says Tesla Cybertruck
    popular tags
    Earnings
    Coronavirus
    Apple
    Amazon
    Coronavirus Impact
    Covid-19
    Covid19
    Google
    Tesla
    mobile iOS Android
    social Facebook Twitter Youtube Linkedin Rss Google News
    Passport to Wall Street About Us Contact Advertise Privacy Policy Terms of Service
    Sign Up
    © 2024 Passport to Wall Street
    Quotes are at least 20 minutes delayed

    Join now and unlock premium features

    Already Have An Account?